TrialBreast cancer research and treatment2019

Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.

Hiroji Iwata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.